PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
152.75%
Net income growth above 1.5x VET's 74.01%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-20.00%
Negative yoy D&A while VET is 8.93%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
116.70%
Well above VET's 84.39% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
82.76%
SBC growth well above VET's 17.90%. Michael Burry would flag major dilution risk vs. competitor’s approach.
36.17%
Less working capital growth vs. VET's 1880.28%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
247.37%
AR growth of 247.37% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.17%
Lower 'other working capital' growth vs. VET's 1880.28%. David Dodd would see fewer unexpected short-term demands on cash.
34.78%
Some yoy increase while VET is negative at -98.65%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
124.10%
Operating cash flow growth above 1.5x VET's 22.71%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
4.65%
Lower CapEx growth vs. VET's 35.92%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
104100.00%
Acquisition growth of 104100.00% while VET is zero at 0.00%. Bruce Berkowitz sees a mild outflow that must deliver synergy to justify the difference.
91.07%
Purchases growth of 91.07% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-4.65%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
4.65%
We have some outflow growth while VET is negative at -1163.98%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
405.15%
Investing outflow well above VET's 14.78%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-457.20%
We cut debt repayment yoy while VET is 42.64%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.